Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Review · January 01, 2020

SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Patients With Atherosclerotic Heart Disease or at Risk for Congestive Heart Failure

Metabolism

 

Additional Info

Metabolism
Differential Indication for SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients With Established Atherosclerotic Heart Disease or at Risk for Congestive Heart Failure
Metab. Clin. Exp. 2019 Dec 07;[EPub Ahead of Print], F Giorgino, I Caruso, J Moellmann, M Lehrke

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading